Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4123322 | 0.86 | OPRM1 (0.49) | CARM1PRMT6ATMTAAR1OPRM1 | |
| SCHEMBL4130314 | 0.77 | CARM1 (0.50) | CARM1PRMT6ATMTAAR1L3MBTL1 | |
| SCHEMBL4046260 | 0.77 | OPRL1 (0.50) | TAAR1OPRM1OPRL1CHRM2CHRM1 | |
| SCHEMBL4118199 | 0.74 | OPRL1 (0.55) | OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL2877571 | 0.73 | OPRL1 (0.56) | OPRM1OPRL1 | |
| SCHEMBL4046256 | 0.71 | ALDH1A1 (0.44) | MEN1KMT2AOPRM1OPRL1 | |
| SCHEMBL4118117 | 0.70 | OPRM1 (0.45) | TAAR1MEN1KMT2AOPRM1OPRL1 | |
| SCHEMBL15681095 | 0.70 | SIGMAR1 (0.47) | OPRM1OPRL1SIGMAR1 | |
| SCHEMBL4132070 | 0.70 | CARM1 (0.48) | CARM1PRMT6ATMTAAR1L3MBTL1 | |
| SCHEMBL1303916 | 0.69 | OPRM1 (0.44) | TAAR1L3MBTL1MEN1KMT2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | CARM1 4222/4885PRMT6 3888/4885ATM 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.